All News

In pharma's AI transformation, the technology was never the hard part — fixing the operating model that has to act on what AI surfaces is.

President Trump moves to nominate Heidi Overton as FDA commissioner, Ron Lanton weighs in on drug pricing's collision with trade policy, and Mohd Haque looks at how pharma leaders are scaling AI across the drug lifecycle.

How drug pricing, tariffs, and manufacturing decisions are becoming connected.

President Trump has reportedly selected White House Domestic Policy Council deputy director Heidi Overton as his nominee for FDA commissioner.

Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the leaders from the rest.

Rohit Tripathi, VP of Industry Strategy at RELEX, lays out the five signals that he believes can measure if the tariff policy is producing structural change.

LEO Pharma, BioMarin, OmniAb, and Chugai post a busy week of pharma dealmaking, RELEX's Rohit Tripathi weighs in on who ultimately pays for tariff-driven input costs, and Spherix Global Insights' Sybil Mead unpacks IRA-driven formulary pressure spreading across payer portfolios.

LEO Pharma agrees to acquire dersimelagon, OmniAb signs a ion channel discovery collaboration with Eli Lilly, Chugai grants GSK an exclusive worldwide license to AID351, and BioMarin acquires Alesta Therapeutics to gain ALE1.

Rohit Tripathi, VP of Industry Strategy at RELEX, talks about who will actually pay for the phased tariff-driven cost increases.

Henlius and Sandoz ink a biosimilars collaboration, ADVI's Tyler Seville makes the case for 340B reform, and RELEX's Rohit Tripathi weighs in on what real pharma reshoring requires.

Henlius Biotech has granted Sandoz exclusive ex-China commercialization rights to up to 10 monoclonal antibody and ADC biosimilars for up to $322 million.

Rohit Tripathi, VP of Industry Strategy at RELEX, discusses how pharmaceutical reshoring demands end-to-end capability not just domestic final assembly.

ADVI’s associate director of market access policy strategy discusses how 340B grew to $100 billion, lost its safety-net purpose, and became a compliance nightmare when the IRA arrived.

From a $1.32 billion rare epilepsy acquisition to AI drug discovery partnerships, biotech IPOs, and a rare disease investment rebound — here's what moved the market this week.

Pharmaceutical Executive releases its 2026 Top 50 company rankings, FDA grants Bristol Myers Squibb's Zenbexus accelerated approval for multiple myeloma, and PwC's Glenn Hunzinger talks the shifting economics of pharma dealmaking.

MedAdvisor Solutions has rebranded as Adheris, restoring a name that has been a fixture in patient engagement for more than three decades.

A changing of the guard atop Pharm Exec’s latest listing of the top biopharma Rx revenue producers reflects an industry being remade in real time, becoming as much a map of franchise quality and market momentum as it is the strategic shifts and bets necessary to turn today’s disruption into tomorrow’s growth.

As trust shifts from a stated value to an operating condition, pharmaceutical leaders face new expectations for how credibility is built, governed and sustained under continuous scrutiny.

Q&A with PwC’s Glenn Hunzinger explores why biopharma M&A investment could approach $300 billion in 2026, how drugmakers are balancing risk amid patent cliffs and policy pressures, and the urgent need to transform healthcare as commercial medical costs climb toward 9%.

FDA has granted accelerated approval to Zenbexus plus daratumumab and Hyaluronidase-fihj and dexamethasone for multiple myeloma after at least one prior line of therapy.

ADVI's Tyler Seville on how the IRA's drug pricing provisions are creating compliance burdens manufacturers can't meet without data they don't have.

A funding roundup covers new IPO and Series A raises across Silence Therapeutics, AbCellera, Beyang Therapeutics, and Remepy, Tyler Seville of ADVI examines the policy concerns building around the 340B Drug Pricing Program, and Pharmaceutical Executive names its 2026 Emerging Pharma Leaders.

From guiding pursuits in artificial intelligence and R&D to scientific marketing and company building, meet Pharm Exec’s new slate of select rising leaders who are helping to shape the next generation of biopharma innovation.

Silence Therapeutics and AbCellera launched respective common share public offerings, and Beyang Therapeutics and Remepy closed $30+ million oversubscribed Series A rounds.

ADVI's Tyler Seville on how 340B has become a financial liability for manufacturers while covered entities expand into wealthy suburban markets.

Mereo BioPharma licenses its lung disease treatment alvelestat to Sentynl Therapeutics, Krieger Scientific's Joseph Morwald examines what's driving a surge in FDA warning letters, and IQVIA's Christopher Wooden and Tom Woods make the case for persona-based HCP engagement.

Why pricing pressure, policy volatility and supply-chain risk are pushing drugmakers toward greater cost and portfolio discipline, without losing sight of investment in innovation.

Overcoming the limits of traditional segmentation through a more connected, responsive and effective approach to health care professional engagement.